rs1800562
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Factors included: apolipoprotein E (ApoE) gene variants (the E4 allele is the strongest confirmed genetic predisposing factor for Alzheimer's disease), the hemochromatosis-HFE gene mutations (H63D and C282Y), diabetes, and stroke.
|
24081379 |
2014 |
rs1800562
|
|
|
0.090 |
GeneticVariation |
BEFREE |
In the Epistasis Project, with 1757 cases of AD and 6295 controls, we studied 4 variants in 2 genes of iron metabolism: hemochromatosis (HFE) C282Y and H63D, and transferrin (TF) C2 and -2G/A.
|
20817350 |
2012 |
rs1800562
|
|
|
0.090 |
GeneticVariation |
BEFREE |
These changes may explain why C282Y-HFE is a risk factor for colon and breast cancer and possibly protective against Alzheimer's disease while H63D-HFE is a risk factor for neurodegenerative diseases.
|
21243428 |
2011 |
rs1800562
|
|
|
0.090 |
GeneticVariation |
BEFREE |
(2004); J Med Genet 41:261-265] reported that epistatic interaction between rs1049296 (P589S) in the transferrin gene (TF) and rs1800562 (C282Y) in the hemochromatosis gene (HFE) results in significant association with risk for AD.
|
20029940 |
2010 |
rs1800562
|
|
|
0.090 |
GeneticVariation |
BEFREE |
In a population-based cohort study, including 268 incident AD patients and 2079 control individuals, we investigated the influence of the HFE C282Y and H63D variants and the apolipoprotein E4 (APOE epsilon 4) allele on the incidence, and age at onset of AD.
|
17628213 |
2009 |
rs1800562
|
|
|
0.090 |
GeneticVariation |
BEFREE |
In contrast, we found a significant negative association of the C282Y HFE mutation with AD, thus supporting a putative protective role of this protein variant in neurodegeneration.
|
19429178 |
2009 |
rs1800562
|
|
|
0.090 |
GeneticVariation |
BEFREE |
APOE epsilon 4 allele was associated with an increased risk of AD and an earlier age at onset, whereas no association was found between TFC2 or HFE C282Y mutation and disease susceptibility.
|
17011669 |
2007 |
rs1800562
|
|
|
0.090 |
GeneticVariation |
BEFREE |
We observed no significant impact of H63D or C282Y heterozygosity on age at AD symptoms onset or diagnosis, age at onset of cognitive symptoms (AD and MCI combined), rates of MCI-to-AD conversion or specific neuropsychological deficits.
|
15013567 |
2004 |
rs1800562
|
|
|
0.090 |
GeneticVariation |
BEFREE |
We have examined the interaction between the C2 variant of the transferrin (TF) gene and the C282Y allele of the haemochromatosis (HFE) gene as risk factors for developing AD.
|
15060098 |
2004 |